Purchase this article with an account.
Livia Tomasso, Lucia Benatti, Alessandro Arrigo, Luigi De Vitis, Michele Cavalleri, Riccardo Sacconi, Lea Querques, Adriano Carnevali, Francesco Bandello, Giuseppe Querques; DYNAMIC FUNCTIONALITY OF RETINAL VESSELS IN EYES WITH CENTRAL SEROUS RETINOPATHY AFTER EPLERENONE. Invest. Ophthalmol. Vis. Sci. 2017;58(8):258.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze dynamic and static characteristics of retinal vessels in eyes with central serous chorioretinopathy (CSC) after Eplerenone by means of Dynamic Vessel Analyzer (DVA).
Patients presenting with CSC and normal subjects (controls) matched for age and sex between May 2016 and November 2016 were enrolled in the study. Participants underwent complete ophthalmologic examination, including optical coherence tomography, dynamic and static retinal vessels analysis.
A total of 31 eyes of 31 subjects (14 eyes for the CSC group treated with Eplerenone, 17 eyes for the control group) were included in the analysis. At baseline (before treatment initiation) dynamic analysis during stimulation by flickering light showed mean arterial dilation of 2.85±1.96% in CSC patients treated with Eplerenone and 4.30±1.63% in healthy eyes (p=0.03); mean venous dilation was 3.20±1.77% and 4.3±1.63%, respectively (p=0.01). Static retinal analysis in CSC patients showed a mean Central Retinal Artery Equivalent (CRAE) of 180±20, a mean Central Retinal Vein Equivalent (CRVE) of 213±15 and a mean arteriovenous ratio (AVR) of 0.84± 0.07. In control subjects mean CRAE was 189±16 and mean CRVE 210±18 (p= 0.22 and p=0.63 respectively vs. CSC eyes) and mean AVR was 0.89±0.04 (p=0.02). Choroidal macular thickness (CMT) was 403±100 μm in CSC eyes, significantly increased compared to control subjects (269±19, p<0.001). After 30 days of Eplerenone, dynamic and static analysis showed no significative differences from baseline; instead, CMT was 313±100 μm, significantly decreased compared to baseline (p=0.02). Compared to control group at day 30, CSC group treated with Eplerenone stil showed a decreased dynamic (mean arterial dilation of 2.22±1.95 and mean venous dilation of 2.69±2.28, p=0.003 and p=0.007 vs. control group).
Dynamic analysis revealed a reduced retinal arterial and venous dilation in response to flicker light stimulation in CSC eyes. Interestingly, after 30 days of Eplerenone, the impaired dynamic did not change despite reduction of CMT.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only